GLOW Peptide Blend
Proprietary blend targeting skin luminosity, elasticity, and repair.
Key Benefits
combines three peptide actives that each target a different aging mechanism for results no single ingredient can achieve
GHK-Cu and Matrixyl together increase structural protein synthesis, restoring skin firmness and reducing wrinkle depth by up to 36%
supports epidermal integrity and moisture retention, reducing transepidermal water loss in aging skin models
addresses dullness at the cellular level by improving cell turnover, reducing oxidative pigmentation, and enhancing light reflection
Active Signaling Pathway
GLOW combines three peptide actives targeting different skin aging mechanisms: GHK-Cu for gene expression reset, Matrixyl (palmitoyl pentapeptide-4) for structural collagen, and Leuphasyl for reducing muscle contraction intensity at expression lines.
Investigated Pathways
Proposed Mechanism
GLOW combines three synergistic peptide actives: GHK-Cu activates collagen and elastin gene expression via copper-mediated signaling; Matrixyl (Palmitoyl Pentapeptide-4) mimics collagen breakdown fragments to trigger repair synthesis via TGF-β pathway; Leuphasyl inhibits neuronal acetylcholine release at the dermal-muscular junction, reducing expression lines. Together they address structural, regenerative, and dynamic aging simultaneously.
Research Highlights
- Matrixyl (Pal-KTTKS) shown in double-blind clinical study to reduce wrinkle volume by 36% over 12 weeks
- GHK-Cu component increases collagen synthesis by up to 70% in fibroblast cultures
- Leuphasyl demonstrated 45% reduction in muscle contraction intensity in in vitro neuromuscular junction models
- Multi-peptide synergy studies show greater efficacy than any single component alone for skin density improvement
Evidence is primarily from in vitro cell studies and animal models. Human data is limited or absent.
For laboratory research only
All Research Systems →For research use only — not for human consumption. No treatment claims.
Full Research Hub →How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 70mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
GLOW combines three synergistic peptide actives: GHK-Cu activates collagen and elastin gene expression via copper-mediated signaling; Matrixyl (Palmitoyl Pentapeptide-4) mimics collagen breakdown fragments to trigger repair synthesis via TGF-β pathway; Leuphasyl inhibits neuronal acetylcholine release at the dermal-muscular junction, reducing expression lines. Together they address structural, regenerative, and dynamic aging simultaneously.
Clinical Context
The GLOW blend is formulated for topical research applications targeting the full spectrum of skin aging: loss of structural proteins (collagen/elastin), reduced regenerative signaling, and dynamic wrinkle formation. The 70mg vial provides sufficient material for extended topical research protocols.
Research Highlights
- Matrixyl (Pal-KTTKS) shown in double-blind clinical study to reduce wrinkle volume by 36% over 12 weeks
- GHK-Cu component increases collagen synthesis by up to 70% in fibroblast cultures
- Leuphasyl demonstrated 45% reduction in muscle contraction intensity in in vitro neuromuscular junction models
- Multi-peptide synergy studies show greater efficacy than any single component alone for skin density improvement
Storage & Reconstitution
Key Studies
The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Pickart L et al.
GHK-Cu component modulates 31.2% of the human genome and increases collagen synthesis by up to 70% in fibroblast cultures.
PubMed →Inhibition of muscle contractions by a peptide acting on the SNARE complex
Blanes-Mira C et al.
Leuphasyl/Snap-8 class peptides reduce SNAP-25 activity by up to 52.7%, reducing expression line depth.
PubMed →Topical peptides as cosmeceuticals
Gorouhi F et al.
Multi-peptide formulations combining collagen-stimulating and neuromuscular-modulating peptides show superior efficacy vs single-ingredient products.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Collagen and elastin synthesis in fibroblasts
Reduces neuromuscular contraction intensity at expression lines
Angiogenesis and tissue perfusion improvement
Pigmentation regulation and skin tone improvement
Side Effects & Adverse Events
- Mild injection site reactions
- Transient skin flushing
- Headache
- Nausea at high doses
- None documented for any component
Contraindications & Interactions
Synergistic Compounds
Amplifies the GHK-Cu component's collagen and gene-regulatory effects for enhanced skin repair.
GLOW blend daily + standalone GHK-Cu 1 mg SubQ for systemic skin repair.
View Compound →Additional SNAP-25 inhibition from standalone Snap-8 amplifies the expression line reduction from GLOW's Leuphasyl component.
GLOW blend AM + Snap-8 topical PM for comprehensive anti-aging protocol.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States